Lataa...
First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma
Checkpoint inhibitors targeted at programmed cell death‐1 receptor (PD‐1) and its ligand (PD‐L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid t...
Tallennettuna:
| Julkaisussa: | Oncologist |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
AlphaMed Press
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6058337/ https://ncbi.nlm.nih.gov/pubmed/29674442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0561 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|